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Abstract—The secretome of human mesenchymal stem cells (MSCs) after osteogenic differentiation of
FetMSC cells in vitro was obtained to develop tissue engineering technologies for bone tissue. For standard
secretome samples a large number of FetMSC cells (7 × 108 cells) were cultured in serum-free conditioned
medium (SFCM). All steps of cell processing were performed in the CompacT SelecT automatic system (Sar-
torius, United Kingdom). The SFCM was concentrated by ultrafiltration, then subjected to dialysis and dried
in a vacuum rotary evaporator. The osteoinductive properties of SFCM concentrate (SFCMC) were tested
on FetMSC cells by means of adding it to the growth medium at different concentrations. There were no
changes in cell morphology during cultivation in the presence of SFCMC. Analysis of the transcription fac-
tors Runx2 and YAP1 (markers of osteogenic differentiation) expression using immunofluorescence staining
and real-time polymerase chain reaction (RT-PCR) showed an increase in their level of expression in the
presence of SFCMC. These findings demonstrate that it is possible to use SFCMC obtained from osteogenic
MSCs to induce differentiation of other (undifferentiated) MSCs. The results are useful for the development
of cell therapy products for bone restoration based on MSCs secretome.
Keywords: mesenchymal stem cells of human bone marrow, cell line FetMSC, osteogenic differentiation,
Runx2, YAP1, secretome, automatic cell culture system
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INTRODUCTION
Currently, tissue engineering of bone tissue is
directed at creating three-dimensional structures, so-
called “grafts,” which are a scaffold populated by stem
cells. Various materials are employed to produce scaf-
folds, often modified with extracellular matrix pro-
teins, growth factors, or genetic constructs to impart
osteoinductive properties to them (Deev et al., 2015).
Improved delivery and preservation of growth factors
is provided by their encapsulation in drug delivery sys-
tems (microspheres, liposomes, hydrogels, etc.) and
their introduction into scaffolds (Porter et al., 2009).
Such incorporation of bioactive substances solves sev-
eral basic problems: targeted delivery of growth factors
with optimal concentration inside the implant, preser-
vation of the biological activity of the molecules, and
controlled release of substances for the required period
of time. However, the optimal composition of the con-
tent is still under discussion (Sundelacruz and Kaplan,
2009). Many processes occur during regeneration, and
so the use of one or more factors is not enough for suc-
cessful tissue repair.
In the past few decades, mesenchymal stem cells
(MSCs) isolated from human tissues and cultivated in
vitro are under active investigation aimed at harness-
ing them for regenerative medicine (Murphy et al.,
2013; Mizukami and Swiech, 2018). The main MSCs
properties are high proliferative activity and the capac-
ity for directed differentiation into connective tissue
cells, as well as production of various substances
involved in the regulation of cellular functions associ-
ated with tissue renewal (Da Silva Meirelles et al.,
2009; Caplan, 2019). In recent years, with the help of
new transcriptomic and proteomic approaches it has
been revealed that MSCs synthesize a complex of bio-
logically active substances (secretome) that coordinate
Abbreviations: SFCM—serum-free conditioned medium; DM—
differentiation medium; SFCMC—SFCM-concentrate; BM—
bone marrow; MSCs—mesenchymal stem cells; RT-PCR—
real-time polymerase chain reaction; FCS—fetal calf serum;
PBS—phosphate buffered saline.492
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growth, division, differentiation, and cell death
(Baglio et al., 2012; Ivanova et al., 2016). The specific
composition of MSCs secretome varies depending on
the donor and tissue origin and alters with certain fac-
tors exposed to cells (Assoni et al., 2017).
Many studies have shown that the cellular micro-
environment has a great influence on the secretome
composition (Kusuma et al., 2017). Analysis of MSCs
secretome revealed a number of proteins, the expres-
sion of which changed during osteogenic differentia-
tion. Kim et al. (2013) identified 315 proteins, of which
more than 200 were differentially expressed during
osteogenesis. It has been shown (Kulterer et al., 2007)
that, in the first 4–5 days, transcription factors and
genes associated with proliferation were predomi-
nantly expressed; then (up to 14 days), the genes
responsible for the production of the extracellular
matrix were; and, from 14 days on, the genes respon-
sible for the mineralization of the matrix.
In a number of studies on the therapeutic applica-
tion of MSCs, it was found that most of the clinical
effects observed during transplantation MSCs were
achieved mainly due to the produced paracrine fac-
tors. Thus, it was demonstrated that the use of factors
produced by cells in the process of differentiation (or
an entire conditioned medium) is a signal for the dif-
ferentiation of stem cells of damaged tissues (Zhong
et al., 2019). In addition, it is also known that these
factors affect on proliferation, chemotaxis, and angio-
genesis, which accelerate reparative processes (Deev
et al., 2015). Therefore, the idea was put forward that
MSCs can be replaced with a secretome without sig-
nificant loss of clinical effect. Another argument for
replacing cells with their secretome is represented by
the intractable questions that exist about the standard-
ization of cellular material, as well as the risks of tumor
transformation (Stanovici et al., 2016).
 To develop a medical technology using a complete
MSCs secretome (or its particular fractions) for the
control of regeneration, the problem of  obtaining a
sufficiently large amount of MSCs secretome and its
standardization arises. When using this technology to
repair damaged bone tissue, the secretome must have
osteoinductive properties. 
The aim of this work was to obtain a lyophilized
concentrate of serum-free conditioned medium
(SFCM) after human MSCs (FetMSC cell line) dif-
ferentiation in the osteogenic direction and examine
its osteoinductive properties in terms of the effect on
cell morphology and their osteogenic differentiation.CELL AND TISSUE BIOLOGY  Vol. 14  No. 6  2020MATERIALS AND METHODS
Cultivation and Induction of Osteogenic Differentiation 
of Human Bone Marrow MSCs Using the Automatic 
Station CompacT SelecT
We used the FetMSC cell line (Collection of Verte-
brate Cell Cultures, Institute of Cytology of the Rus-
sian Academy of Sciences, St. Petersburg), obtained
from MSCs of human embryonic bone marrow (Kry-
lova et al., 2012). Cells were thawed and cultured on
75-cm2 f lasks (T75) under the good manufacturing
conditions of the Laboratory of Biomedical Technol-
ogies and Testing with a pilot production facility
(Center of Cell Technologies of the Institute of Cytol-
ogy). Cells were multiplied in an automatic CompacT
SelecT cell culture station (Sartorius, United King-
dom) (Fig. 1) for standardize all stages of cultivation
and obtain a serum-free conditioned medium
(SFCM). All subsequent cellular processing was per-
formed using the capabilities of this robotic system.
For this purpose, we have developed algorithms for
sequential automated manipulations. The sequential
steps of cell processing and media exchange using
CompacT SelecT are presented in Table 1. 
The cells were cultured in DMEM medium under
aseptic controlled conditions: a temperature of 37°C,
humidity of 98%, and composition of the gas medium
of 5% CO2. For cell growth, a DMEM/F12 medium
(Gibco, USA) containing 10% bovine embryo serum
(SEC) (Gibco, USA) was used. The CompacT SelecT
system determines the confluence of cells in the cul-
ture at a frequency set by the operator, and, when the
set value is reached, it performs an automated cell sub-
culture. The collection of conditioned medium, cell
counting, and assessment of their viability were also
done in an automatic mode. This approach ensured
homogeneity of the obtained cell population and the
standardization of the conditioned medium collected
from a large volume of cells into a sterile vessel for sub-
sequent analysis.
After accumulating a sufficient number of cells the
culture medium was replaced with differentiation
medium (DM), containing a complete DMEM/F12
culture medium supplemented with dexamethasone
(0.1 μM), ascorbic acid (50 μM), and sodium β-glyc-
erophosphate (10 mM) for stimulation differentiation
of MSCs in the osteogenic direction (Pittenger et al.,
2001). After 72 h, the culture medium was removed,
the cell monolayer was washed three times with PBS,
supplemented with serum-free DMEM/F12 growth
medium, and cultured for 72 h. The medium was then
automatically collected under aseptic conditions in a
sterile container. This medium was assigned as
SFCM, and its components secreted by differentiated
MSCs were designated as secretome of osteogenic
MSCs. During the cultivation, the induced cells
secreted into the growth medium metabolites pro-
duced in the process of osteogenic differentiation.
After collection of SFCM, the cell viability and level of
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Fig. 1. CompacT SelecT automatic system for cell cultivation and analysis (Sartorius, United Kingdom). Working areas of the sys-
tem: (1) incubator with loaded f lasks, (2) robotic arm of the device for handling solutions and flasks with cells, (3) area for bottling
nutrient media and other liquids, (4) IncuCyte module (Essen Biosciences, United States), (5) ViCell cell counter (Beckman,




1 2expression of the transcription factors Runx2 and
YAP1 activated at the early stages of osteogenic induc-
tion (Yagi et al., 1999; Komori et al., 2011), were
assessed with real-time polymerase chain reaction
(RT-PCR) (see the method below).
Preparation of the Serum-Free Conditioned Medium 
Concentrate from Induced MSCs (SFCMC)
The collected SFCM was centrifuged at 1660 g for
10 min. The obtained supernatant was passed through
a filter with 0.22-μm pores and then concentrated by
ultrafiltration in tangential f low in the Vivaflow® 200
system (Sartorius, Germany) using a membrane mod-
ule with a cutoff threshold for molecules with a molec-
ular weight of 10 kDa. The resulting solution was dia-
lyzed using the same system by adding deionized water
to the sample container (diafiltration). The concen-
trate purified from salts was dried in a Rotavapor®
R-210 vacuum rotary evaporator (Buchi, Germany)
and placed in a microcentrifuge tube. Experiments on
SFCMC production were performed in the Research
Laboratory “Cellular, Assisted Reproductive, and
DNA Technologies” (Belgorod State National
Research University).
The lyophilized concentrate (SFCMC) was diluted
in serum-free DMEM/F12 medium (Rosmedbio,
Russia) and sterilized by passing through a filter with
22-μm pores under aseptic conditions. This stockC
solution, with a concentration of 33.33 mg/mL, was
further added to the nutrient medium (in the absence
of fetal calf serum (FCS)).
Intravital Study of MSCs Morphology
FetMSC cells (passages 4–5 after decryopreserva-
tion) were seeded into 24-well plates with 100 thou-
sand cells per well and cultivated for 1 and 7 days under
standard conditions. To examine the possible effect of
SFCMC on the cell morphology, the stock solution
was added to the culture medium (not containing
FCS) in concentrations of 0.33 and 0.66 mg/mL. Dig-
ital imaging of cell cultures in real time was carried out




FetMSC cells were seeded on glasses, placed on the
bottom of the wells of 24-well plates (105 cells per
glass), and cultured for 7 days under standard condi-
tions. To study the osteoinductive properties of
SFCMC, it was added to the culture medium without
FCS at concentrations of 0.33 or 0.66 mg/mL. Cells
growing in DM were used as a positive control; cells
maintained under standard conditions served as a neg-
ative control. On the seventh day of cultivation, the
growth medium was discarded; the cells were washedELL AND TISSUE BIOLOGY  Vol. 14  No. 6  2020
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Table 1. Cell processing steps using the automatic station CompacT SelecT
CF—confluence; CM—culture medium; DM—differentiation medium, FBS—fetal calf serum; PBS—phosphate buffered saline;
SFCM—serum-free conditioned medium; SFM—serum-free medium.
Step Description Culture medium CompacT SelecT manipulations Control parameters
1. Growth of 
FetMSC cells
Mass-cultivation of 
cells in order to obtain 
50 T175 f lasks at pas-
sage 5
CM:
DMEM/F12 + 10% 
FBS
CF control is performed every 
12 hours in each vial using the 
IncuCyte module. When the CF 
reaches 85%, the cells are subcul-
tured 1 : 5. Cell vitality and num-
ber are controlled by ViCell cell 
counter. Cells passaging are 
included: draining the medium 
from the f lasks, washing with PBS, 
adding trypsin with shaking the 
f lask, adding CM, mixing the cell 
suspension by pipetting and trans-
ferring to new flasks
Cell vitality:
95–100%.
The number of cells 
per 1 bottle of T175: 
(12–16) × 106.
Plotting a growth 




tion CM in 50 T175 
f lasks with cells (CF = 
40–60%) to DM
DM:
DMEM/F12 + 10% 
FBS + 0.1 μM dexa-
methasone, +50 μM 
ascorbic acid, 
+10 mM sodium β-
glycerophosphate
Evaluation of CF before replace-
ment CM is estimated by Incu-
Cyte module. Adding DM and 
placing the vials in an incubator 
for 72 h. Assessment of cell mor-
phology during differentiation
CF before





tion DM to SFM in 
50 T175 flasks with cells 
in 72 h of induction
SFM:
DMEM/F12
CF assessment before changing 
the medium (IncuCyte module). 
Washing the vials with PBS cells 
3 times, adding SFM and placing 
the vials in an incubator for 72 h
CF before
by changing the 
environment:
80–90%
4. Collection of 
SFM (SFCM)
SFCM from 50 T175 
f lasks
Sequential replacement of SFCM 
from 50 f lasks into a clean con-
tainer (by means of robotic arm). 
Sealing the container and handing 
it over to the operator. Selectively 
medium is collected from 5 vials 
and cells are removed by trypsin 
treatment. Their vitality is ana-
lyzed by the ViCell counter
Cell vitality:
90–100%with PBS and fixed in a 10% formalin solution (Bio-
Vitrum, Russia). Mouse monoclonal antibodies to
Runx2 protein (ab76956) and rabbit monoclonal anti-
bodies to YAP1 (ab205270; Abcam, United Kingdom)
were used as primary antibodies. Fluorescently labeled
(AlexaFluor® 488) goat polyclonal antibodies to
mouse IgG (ab150113) and goat polyclonal antibodies
(AlexaFluor® 594) to rabbit IgG (ab150080) (Abcam,
United Kingdom) were used, respectively, as second-
ary antibodies. After incubation with secondary anti-
bodies, the cells were mounted in DAPI-FluoroShield
medium (Vector Laboratories, United States) con-
taining DAPI (the intercalating dye for staining cell
nuclei).CELL AND TISSUE BIOLOGY  Vol. 14  No. 6  2020Cells imaging was performed with a ZOE™
inverted confocal microscope Fluorescent Cell Imager
(United States).
Real-Time Polymerase Chain Reaction
To detect the expression of the runx2 and yap1
genes, FetMSC cells were seeded into 24-well plates,
105 cells per well, and cultivated for 3, 7, and 14 days
under standard conditions. Osteoinductive properties
of SFCMC were tested by its addition in serum-free
culture medium at concentrations of 0.33 or
0.66 mg/mL. Cells cultivated in DM and Hos human
osteosarcoma cells (TE85, clone F5) from the Collec-
tion of Vertebrate Cell Cultures, Institute of Cytology,
496 ALEKSANDROVA et al.Russian Academy of Sciences (St. Petersburg) were
used as positive controls. Cells cultivated under stan-
dard conditions served as negative control.
RNA from cells was isolated using Lira reagent
(Biolabmix, Russia) containing phenol and guanidine
thiocyanate. Reverse transcription was performed
with the RTM-MuLV-RH Reverse Transcription Kit
(Biolabmix, Russia). Oligonucleotide primers to
runx2 gene (5'-ACCGAGACCAACAGAGT-
CATTTA-3', 3'-GTGTCACTGTGCTGAAGAGG-
5', 119 bp) and to yap1 gene (5'-AACAG-
CAAGAACTGCTTCGG-3', 3'-GCAGGGCTA-
ACTCCTGACAT-5', 84 bp) were selected by the
authors of this work. Primers to ppia gene sequences
(5'-AGACAAGGTCCCAAAGAC-3', 3'-ACCAC-
CCTGACACATAAA-5', 118 bp) and hprt1 gene (5'-
GACCAGTCAACAGGGGACAT-3', 3'-CCTGAC-
CAAGGAAAGCAAAG-5', 132 bp) were used as ref-
erence. Highly purified primers were synthesized at
OOO Biosset (Novosibirsk, Russia). RT-PCR was
performed using the Maxima SYBRGreen kit (Ther-
moScientific, United States) in AriaMx amplifier
(Agilent Technologies, United States).
Gene expression analysis was performed at the
Core Medical Genomics Facility of the Tomsk
National Research Medical Center (Tomsk NRMC)
of the Russian Academy of Sciences.
RESULTS AND DISCUSSION
Production of SFCMC from Human Osteogenic MSCs
For standard cultivation of FetMSC, a special
algorithm was developed that constructed the program
for the robot. The whole process of scaling and col-
lecting of SFCM described below was carried out with
this program. Cells were cultivated in the CompacT
SelecT system for five passages from one T75 flask
transferred to the robot. The system performed cell
subculture upon reaching the confluence of 85%. For
this, the cell confluence in culture was monitored
every 12 h. The cells were subcultured in a 1 : 5 ratio,
and the medium was replaced at least once within
3 days. By the 5th passage, 7 × 108 cells were accumu-
lated on 50 T175 flasks. The viability of cells ranging in
size from 10 to 50 μm was 98–100% during the entire
processing. After obtaining 50 f lasks of cells with a
confluence of 50–60%, the system replaced the
growth medium with the induction medium (DM) for
MSCs differentiation in the osteogenic direction.
After cell differentiation (72 h), the medium was
exchanged with the serum-free medium and the cells
were cultured for 72 h. A total of 1000 mL of SFCM
was collected.
The cell shape during the entire time of the experi-
ment remained fibroblast-like, and the cells formed a
monolayer (Fig. 2). After collecting SFCM, two ran-
domly selected f lasks were treated with lysis buffer for
RNA isolation immediately after the medium collec-C
tion. Next, we studied the expression of the runx2 and
yap1 genes in cells in comparison with positive con-
trols (cells in DM and Hos cells). Expression of the
runx2 gene in the positive control and Hos cells was
five and three times higher than in the negative con-
trol, respectively. Expression of the yap1 gene in the
positive control was twice that in the negative control.
In Hos cells, it did not differ from the negative control.
In FetMSC cells after SFCM collection, the level of
expression of the runx2 gene was twice as high as in the
negative control, but did not reach the level of expres-
sion in the positive control. Expression of yap1 was
1.7 times higher than in the negative control, practi-
cally reaching the corresponding value in the positive
control.
Osteoinductive Properties of SFCMC
Influence of SFCMC on MSCs Morphology
Live cell imaging in the presence of SFCMC did
not reveal obvious morphological differences between
the samples (not shown). The cells actively prolifer-
ated and after 7 days of cultivation, created a dense
monolayer. Supposedly, the rather clear morphologi-
cal changes that occur during osteogenesis have not
yet appeared during this time.
Accumulation of Transcription Factors Runx2 
and YAP1 in the Presence of SFCMC
The cells bound Runx2 antibodies and exhibited
green fluorescence in their cytoplasm (Fig. 3). Fluo-
rescence was observed in cells in the presence of
SFCMC at both concentrations (0.33 and
0.66 mg/mL) for 7 days at approximately the same
level (Figs. 3c, 3d). Its level was lower than in the
osteogenic medium (Fig. 3b), but higher than in the
growth medium (Fig. 3a). At the same time, staining
was detected unevenly on the preparations; therefore,
it was difficult to make a quantitative comparison.
Cells stained with antibodies to YAP1 exhibited
fluorescence in nuclei (Fig. 4). On preparations of cell
cultured in the presence of SFCMC, the majority of
nuclei had a red color (Figs. 4c, 4d), in contrast to the
negative control (Fig. 4a), but less than cells cultured
in the osteogenic medium (Fig. 4b).
Detection of runx2 and yap1 Gene Expression
by RT-PCR
Cultivation of cells in the presence of SFCMC
increased expression of the runx2 gene already on the
third day (2.5 times at an SFCMC concentration of
0.66 mg/mL and five times with 0.33 mg/mL SFCMC
(Fig. 5). The maximum expression was observed after
7 days (45 and 12 times higher than the negative con-
trol at an SFCMC concentration of 0.66 and
0.33 mg/mL, respectively). On the third and seventh
days, the expression exceeded even the values of theELL AND TISSUE BIOLOGY  Vol. 14  No. 6  2020
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Fig. 2. FetMSC cells during cultivation in the CompacT SelecT robotic system. Cell growth curve after the last subculture. Sub-
cultured cells have fibroblast-like morphology. Inverted microscopy. Ob.: 10×.






















After collection of SFCM
days
Fig. 3. Immunofluorescent staining of Runx2 protein (green color) with monoclonal antibodies in FetMSC cells after cultivation
in (a) growth and (b) osteogenic media, as well as in the presence of SFCMC at a concentration of (c) 0.33 and (d) 0.66 mg/mL
for 7 days. Cell nuclei are stained with DAPI (blue). Confocal microscopy. Ob: 20×.
100  μm 100 μm
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Fig. 4. Immunofluorescent staining of the YAP1 protein (red color) with monoclonal antibodies in FetMSC cells after cultivation
in (a) growth and (b) osteogenic media, as well as in the presence of SFCMC at a concentration of (c) 0.33 and (d) 0.66 mg/mL
for 7 days. Cell nuclei are stained with DAPI (blue). Confocal microscopy. Ob: 20×.




(b)positive control (DM) (by two to five and two to seven
times, respectively). As in the positive control, on the
14th day of the experiment, the expression of the runx2
gene decreased; nevertheless, it remained three times
higher than in the negative control. Expression of the
yap1 gene was characterized by slightly different
dynamics. In cells cultivated with SFCMC, it only
slightly increased relative to the negative control on
the third day (1.6 times at an SFCMC concentration
of 0.66 mg/mL). On the seventh day of cultivation, on
the contrary, the expression exceeded the correspond-
ing value of the negative control only for the SFCMC
concentration of 0.33 mg/mL (3.2 times relative to the
negative control and 1.4 times relative to the positive
control). Finally, after 14 days, the expression
exceeded the values of the negative control for both
concentrations of SFCMC (3.3 times at 0.66 mg/mL
and 2.9 times at 0.33 mg/mL), being slightly lower
than the positive control values (1.1–1.3 times). For
the other reference gene, hprt1, similar results were
obtained.
Thus, the dynamics of the runx2 gene expression
indicates that SFCMC has an osteoinductive activity
that exceeds that of known methods of osteoinduc-
tion. At the same time, SFCMC has a slightly lower
potential for inducing yap1 gene expression.C
CONCLUSIONS
Large-scale cell culturing is usually used to obtain
a standard cell mass for further research or banking. In
this work, the method was applied to manufacture an
experimental sample of the SFCM conditioned
medium containing the secretome of osteogenic cells.
The developed technology includes not only the
growth of cell mass, but also further experimental cul-
tivation of cells under particular conditions (medium
condition). As a result, we developed and tested an
algorithm for the operation of the automatic station
CompacT SelecT for the production of large cell mass
under standard conditions in order to obtain SFCM
from cultured human MSCs (FetMSC cells) after
their differentiation in the osteogenic direction. The
studies of the effect of secretome concentrate (SFCM)
on in vitro cells demonstrated its positive effect on the
capacity of MSCs for osteogenic differentiation. It was
shown that this method makes it possible to maintain
cellular activity, including growth factors that control
the ability of cells to differentiate in the osteogenic
direction.
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